2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5786 Efficacy of talquetamab (talq) retreatment following talq bridging for CAR-T cell therapy in multiple myeloma (MM): Data from the US MM immunotherapy consortium

Darren Pan, MD, Kevin Robert Reyes, MD2, Alexandria Jensen, Phd3, Christopher J. Ferreri, MD4, Christoph Schaefers, MD5, Rahul Banerjee, MD6, Ariel Grajales-Cruz, MD7, Andrew J. Portuguese, MD8, Melinda Tan, MD9, Danai Dima, MD10, Murali Janakiram, MBBS11, Noa Biran, MD12, Cindy Varga, MD,BSc13, Poy Theprungsirikul, MD14, Omar Nadeem, MD15, Shonali Midha, MD16, Emily C. Liang, MD17, Lekha Mikkilineni, MD, MA18, Masooma Shifa Rana, MBBS19, Bruno Almeida Costa, MD20, Mackenzie Maberry, MD21, Hector Garcia Pleitez, MD22, Binoy Yohannan, MD23, Chenyu Lin, MD24, Alissa Visram, MD, MPH25, Hira Mian, MD26, Nisha Joseph, MD27, Timothy O'Brien, MD28, Shahzad Raza, MD29, Karen Sweiss, PharmD30, Ana Maria Avila Rodriguez, MD31, Kelley Julian, PharmD, BCOP32, Megan M Herr, PhD33, Francesca Cottini, MD34, Ashley Rosko, MD35, Faiz Anwer, MD36, Samer Al Hadidi, MD37, James A Davis, PharmD, BCOP38, Larry D Anderson Jr, MD, PhD39, Anthony Dominick, DO40, Omar Alexis Castaneda Puglianini, MD41, Rebecca Gonzalez, PharmD42, Doug W. Sborov, MD, MS43, Jack Khouri, MD44, Doris K. Hansen, MD45, Yi Lin Jr, MD, PhD46, Oren Pasvolsky, MD47, Surbhi Sidana, MD48, Ajai Chari, MD49, Aimaz Afrough, MD50
1 University of California, San Francisco, San Francisco, California, United States
2 University of California, San Francisco, San Francisco, California, United States
3 Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, United States
4 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
5 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampda, Florida, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
13 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States
18 Stanford University School of Medicine, Stanford, California, United States
19 Stanford University School of Medicine, Stanford, California, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 University of Minnesota, Minneapolis, Minnesota, United States
24 Duke Cancer Institute, Durham, North Carolina, United States
25 McMaster University, Hamilton, Ontario, Canada
26 McMaster University, Hamilton, Ontario, Canada
27 Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
28 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
29 Cleveland Clinic, Cleveland, Ohio, United States
30 University of Illinois Chicago, Chicago, Illinois, United States
31 University of Illinois Chicago, Chicago, Illinois, United States
32 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
33 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
34 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
35 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
36 Cleveland Clinic, Cleveland, Ohio, United States
37 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
38 Medical University of South Carolina, Charleston, South Carolina, United States
39 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
40 Medical University of South Carolina, Charleston, South Carolina, United States
41 H. Lee Moffitt Cancer Center and Research Institute, Tampda, Florida, United States
42 H. Lee Moffitt Cancer Center and Research Institute, Tampda, Florida, United States
43 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
44 Cleveland Clinic, Cleveland, Ohio, United States
45 H. Lee Moffitt Cancer Center and Research Institute, Tampda, Florida, United States
46 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
47 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
48 Stanford University School of Medicine, Stanford, California, United States
49 University of California, San Francisco, San Francisco, California, United States
50 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States

Introduction: Talq is a GPRC5DxCD3 bispecific antibody increasingly used in MM as a bridge to anti-BCMA CAR-T cell therapy (talq bridging). This approach takes advantage of the rapid cytoreduction that talq frequently produces without affecting the BCMA target while allowing for a talq-free interval which can relieve GPRC5D-related oral, skin, and nail toxicities. Early data from finite-duration teclistamab (tec) therapy in the LimiTEC study and with cevostamab have shown disappointingly low response rates upon retreatment. Although talq bridging is increasingly used, its impact on future talq use has yet to be characterized. Therefore, we conducted a multicenter retrospective study to assess the efficacy of talq retreatment in MM patients who received talq bridging.

Methods: Within the US MM Immunotherapy consortium, we studied patients with MM who were treated with and responded to talq bridging (partial response [PR] or better), discontinued talq for reasons other than progressive disease (PD), later had PD after a ≥3-month talq-free interval, and were rechallenged with talq. Primary refractoriness to talq or use of talq plus other bispecific antibodies on retreatment were excluded. Time from apheresis to start of lymphodepletion was used as a surrogate for duration of talq exposure in the setting of talq bridging.

Results: A total of 13 patients were retreated with talq after previously responding to talq bridging. Median follow-up from apheresis was 19.2 months and all patients were bridged to ciltacabtagene autoleucel (cilta-cel). At the time of initial talq exposure, patients had a median age of 56 years, a median of 5 prior lines of therapy; 76.9% were triple-class refractory, 53.8% had high-risk cytogenetics, and 46.2% had true extramedullary disease (EMD). Best responses to talq bridging were 5 PR, 3 very good partial response (VGPR), and 5 at least complete response (CR). Median duration of initial talq treatment was 58 days (IQR 47-82 days). Median interval from initial talq exposure to retreatment was 315 days (IQR 270-349 days). Talq retreatment was the immediate next LOT in all patients.

Among these 13 patients, 11 had response data available. Best response with talq retreatment was PD in 4, PR in 3, VGPR in 3, and CR in 1 for an overall response rate of 64% (36% VGPR+). Starting from time of talq retreatment, median progression-free survival was 4.6 months, while median overall survival was not reached (70% at 12-months).

Discussion: This is the first report of talq retreatment following talq bridging and demonstrates that talq retreatment is feasible and efficacious in 64% of patients. However, approximately one-third of previously talq-sensitive patients do not have responses with subsequent exposure. Importantly, since talq bridging has only recently become commonplace, the current study population is limited to talq bridging patients with relatively quick relapses on cilta-cel, enriching the study population for higher-risk disease and EMD. The extent to which the observed decrement in efficacy represents the impact of prior talq exposure versus aggressive disease biology remains uncertain. Future studies with larger cohorts, patients with more favorable disease biology, and correlative analyses are needed to better define predictors of talq retreatment efficacy and to determine whether talq-based combinations can overcome the reduced responses observed.

Darren Pan, MD: Johnson & Johnson - Research Funding; Regeneron - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)